Gino In

TitleAssistant Professor of Clinical Medicine
InstitutionUniversity of Southern California
AddressGNH 3821
Health Sciences Campus
Los Angeles CA 90089-9324
Phone+1 323 226 7622
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Southern California, Los Angeles, CAFellowship2016Hematology/Oncology
    SUNY Downstate Medical Center, Brooklyn, NYResidency2011Internal Medicine
    SUNY Downstate Medical Center, Brooklyn, NYInternship2010
    Ross University, North Brunswick Township, NJMD2010Medicine
    Emory University, Atlanta, GAMPH2006Environmental/Occupational Health
    Emory University, Atlanta, GABS2002
    Collapse Awards and Honors
    University of Southern CaliforniaChief Medical Oncology Fellow

    Collapse Overview 
    Collapse Overview
    Gino K. In is a medical oncologist who specializes in solid tumor and cutaneous oncology. He completed his residency training in hematology and oncology at the University of Southern California Keck School of Medicine, where he was the chief medical oncology fellow. He has stayed on to serve as Assistant Professor of Medicine in the Division of Oncology.

    Dr. In’s research focus includes the multi-disciplinary management of melanoma and other skin cancers, with a specific interest in improving cancer outcomes among underserved populations, including adolescents and young adults, and Hispanics. He is actively involved with the USC Adolescent and Young Adult (AYA) Oncology Group, the USC Skin Cancer Task Force, and the Melanoma Prevention Working Group.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Lara KM, In GK, Matcuk GR, Mehta A, Hu JS. Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma. JAAD Case Rep. 2018 Nov; 4(10):1004-1006. PMID: 30450405.
      View in: PubMed
    2. Nazemi A, Higgins S, Swift R, In G, Miller K, Wysong A. Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature. Dermatol Surg. 2018 Jun 08. PMID: 29894433.
      View in: PubMed
    3. In G, Mason J, Lin S, Newton PK, Kuhn P, Nieva J. Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Converg Sci Phys Oncol. 2017 Sep; 3(3). PMID: 30283700.
      View in: PubMed
    4. In GK, Mason J, Lin S, Newton P, Kuhn P, Nieva J.Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Convergent Science Physical Oncology. 2017; 3(3).
    5. Miller KA, In GK, Jiang SY, Ahadiat O, Higgins S, Wysong A, Cockburn MG.Skin Cancer Prevention Among Hispanics: a Review of the Literature. Epidemiology. 2017.
    6. In GK, Hu JS, Tseng WW. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Aug; 9(8):533-550. PMID: 28794805.
      View in: PubMed
    7. In GK, Nieva J.Emerging Chemotherapy Agents in Lung Cancer: Nanoparticle Therapeutics for Non-Small Cell Lung Cancer. Transl Cancer Res. 2015; 4(4):340-355.
    8. In G, Dorff T. Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies. Urol Clin North Am. 2015 Aug; 42(3):347-57. PMID: 26216822.
      View in: PubMed